secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179418
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q2 2025 net loss $27.0M; cash $177.3M; Phase 3 CoMpass nearing enrollment end
--------------------------------------------------------------------------------

- Net loss $27.0M in Q2 2025 vs $20.3M in Q2 2024; R&D expenses rose to $22.9M from $16.9M.
- Cash and marketable securities $177.3M; $75M equity financing closed; cash runway into first half 2027.
- Phase 3 CoMpass trial in early choroidal melanoma actively enrolling; >240 patients pre-screened; enrollment may complete by end of 2025.
- Phase 1b/2 NMIBC trial actively enrolling; new bel-sar formulation patent filed for convenient in-office use.
- Phase 2 trial in metastases to choroid protocol amended to include all solid tumors; initial data expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312525179418/0001193125-25-179418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312525179418/aura-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer